Abstract:Coronary heart disease is characterized by both lipid deposition and chronic inflammation, and residual cardiovascular risk persists despite lipid-lowering therapy. As an upstream inflammatory cytokine, interleukin-6 (IL-6) activates the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway through classical and trans-signaling, thereby contributing to endothelial injury, foam cell formation, plaque instability, and the induction of C-reactive protein expression. Mutations in clonal hematopoiesis-related genes, including DNA methyltransferase 3 alpha (DNMT3A), Tet methylcytosine dioxygenase 2 (TET2), additional sex combs-like 1 transcriptional regulator (ASXL1), and Janus kinase 2 (JAK2), may further enhance IL-6 signaling. Ziltivekimab, a monoclonal antibody targeting IL-6, has been shown in a phase Ⅱ trial to significantly reduce high-sensitivity C-reactive protein, fibrinogen, and other inflammation- and thrombosis-related biomarkers. A phase Ⅲ cardiovascular outcomes trial is currently evaluating its effects on hard clinical endpoints, including myocardial infarction, stroke, and cardiovascular death, indicating that IL-6-targeted therapy has progressed from mechanistic and surrogate-endpoint studies to clinical outcome validation. This review summarizes the underlying mechanisms, genetic drivers, and clinical significance of IL-6, providing a reference for precision anti-inflammatory therapy in coronary heart disease.